.png)
In this episode of The Genetics Podcast, host Patrick Short talks with Martin Borch Jensen, Co-founder and Chief Scientific Officer at Gordian Biotechnology, about his journey into the biology of aging and the innovative approaches his company is using to tackle age-related diseases. They discuss the science behind aging, intermittent fasting, and Gordian's cutting-edge tools for drug development.
Genetic screening is poised to significantly enhance public health by improving the way we detect, prevent, and manage diseases. However, successfully integrating genetic screening into public health systems requires strategic planning across several key areas. Our report, "Strategic pathways for integrating genetic screening into public health," outlines the essential steps needed, focusing on infrastructure development, policy, and international collaboration.
In the latest episode of The Genetics Podcast, host Patrick Short welcomes Dr. Tony Cox, CEO of the UK Biocentre, to discuss his 20 years of experience at the Wellcome Sanger Institute. Dr. Cox also shares his journey from joining the UK Biocentre at the onset of the COVID-19 pandemic to leading one of the UK's Lighthouse Labs, a role for which he was awarded an Officer of the Order of the British Empire (OBE).
Genetic sequencing has significantly advanced our ability to detect individuals at increased risk of developing specific conditions and to identify diseases in their earliest stages. Predictive genetic testing can reveal susceptibilities to conditions like cancer, while diagnostic testing enables the detection of diseases before symptoms arise. These tools offer the potential for more personalized and effective healthcare. However, with these advancements come important considerations around accessibility, ethics, and practical implementation. This blog will explore how genetic testing is shaping the future of early disease detection and the essential need for equitable access to these critical technologies.
In the latest episode of The Genetics Podcast, host and Sano CEO Patrick Short explores population genomics and precision medicine with Dr. Mike Gaziano. Dr. Gaziano is a Professor of Medicine at Harvard, working at VA Boston and Brigham and Women's Hospital. He is one of the two principal investigators of the Million Veterans Program (MVP), the largest health system-based mega biobank in the world.
Decreasing costs, improved technologies, and increased prevalence of chronic and infectious disease are driving an explosion in the use of genetic testing across research, clinical trials, and public health. Healthcare is on the cusp of an unprecedented opportunity to integrate sequencing as a core initiative which not only improves individual patient outcomes and population-scale research, but reduces burden on stressed health systems and opens the door to international collaboration on an unparalleled scale.
In the latest episode of The Genetics Podcast, host and Sano Genetics CEO Patrick Short explores the evolving landscape of personalized medicine with Dr. Scott Weiss, a Professor of Medicine at Harvard Medical School and Associate Director of the Channing Division of Network Medicine (CDNM) at Brigham and Women's Hospital (BWH).
The integration of precision medicine into healthcare systems presents significant economic opportunities. By focusing on tailored treatments, precision medicine not only promises improved patient outcomes but also drives cost savings and efficiency across the healthcare sector. In this blog, we explore the economic impacts of precision medicine and the necessity of supportive policy measures to fully harness its benefits. This strategy not only fosters economic growth but also improves patient care and enhances the efficiency of the overall healthcare system.
Medical research is moving faster than ever, and while this is exciting news for patients waiting for new and better treatments, it also highlights the bottlenecks that are slowing the process down. One such bottleneck is clinical trial patient recruitment; a third of all delays for Phase III studies are caused by difficulties finding patients to take part. And while it’s estimated that recruitment costs make up 40% of all trial expenditures, 80% of studies fail to meet their enrollment deadlines. These delays are costly, too – for many sponsors, every month delayed can cost an additional $1 million.
Despite being in the early stages, AI's integration into genomics has already created a wave of change in many aspects of healthcare.